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The effects of acute amiodarone infusion on dynamics of
ventricular fibrillation (VF) are unclear. Six isolated swine
right ventricles (RVs) were studied in vitro. Activation pat-
terns during VF were mapped optically, whereas action po-
tentials were recorded with a glass microelectrode. At base-
line, VF was associated with frequent spontaneous wave
breaks. Amiodarone (2.5 g/ml) reduced spontaneous wave
breaks and increased the cycle length (CL) of VF from 83.3 
17.8 ms at baseline to 118.4  25.8 ms during infusion (P 
0.05). Amiodarone increased the reentrant wave front CL
(114.4  15.5 vs. 78.2  19.0 ms, P  0.05) and central core
area (4.1  3.8 vs. 0.9  0.3 mm2, P  0.05). Within 30 min
of infusion, VF terminated (n  1), converted to ventricular
tachycardia (VT) (n 1) or continued at a slower rate (n 4).
Amiodarone flattened the APD restitution curves. We con-
clude that amiodarone reduced spontaneous wave breaks. It
might terminate VF or convert VF to VT. These effects were
associated with the flattening of APD restitution slope and
increased core size of reentrant wave fronts.
optical mapping; action potential duration restitution; sud-
den death; pharmacology; antiarrhythmic agents
INTRAVENOUS AMIODARONE is a commonly used antiar-
rhythmic agent in the treatment of life-threatening
ventricular tachyarrhythmia (13). However, few stud-
ies have examined the mechanisms by which amioda-
rone is effective against ventricular fibrillation (VF).
We (27) previously proposed that transition from ven-
tricular tachycardia (VT) to VF is a transition to spa-
tiotemporal chaos, with similarities to the quasi-peri-
odic route to chaos seen in fluid turbulence. In this
scenario, chaos results from the interaction of multiple
causally independent oscillatory motions. Computer
simulations and animal experiments suggest that the
destabilizing oscillatory motions during spiral-wave
reentry arise from restitution properties of action po-
tential duration (APD). Modifying APD restitution
characteristics can prevent spiral-wave breakup in
simulated cardiac tissue, suggesting that drugs with
similar effects in real cardiac tissue may have antifi-
brillatory efficacy (the restitution hypothesis). Intrave-
nous amiodarone is effective in treating patients with
life-threatening ventricular arrhythmias and is now
included in the new American Heart Association guide-
lines for advanced cardiopulmonary life support (7).
The purpose of this study was to investigate the mech-
anisms underlying antifibrillatory effects of amioda-
rone and to determine whether flattening of APD res-
titution may be involved in its antifibrillatory actions.
METHODS
The research protocol was approved by the institutional
animal care and use committee and followed the guidelines of
the American Heart Association. The details of the isolated
right ventricle (RV) preparation have been reported else-
where (9). Briefly, six farm pigs (25–32 kg) were anesthetized
and the hearts were removed. The RV was placed in tissue
bath with the epicardial side up and was perfused with
oxygenated Tyrode solution (37.0  0.5°C, pH 7.4  0.5)
through the right coronary artery. The composition of the
Tyrode solution was the following (in mM): 125.0 NaCl, 4.5
KCl, 0.5 MgCl2, 0.54 CaCl2, 1.2 NaH2PO4, 24.0 NaHCO3, 5.5
glucose, and 50 mg/l albumin. Two bipolar electrodes were
attached to the epicardial surface: one for continuous record-
ing and the other for pacing. Two Endotak defibrillation
electrodes (Guidant) were placed on two opposing sides of the
tissue bath for electrical defibrillation.
Optical mapping system. We stained four of six RVs and
optically mapped the patterns of epicardial activation. The
optical mapping system used in the present study was simi-
lar to the one described previously (15). Fluorescence from
Address for reprint requests and other correspondence: P.-S. Chen,
Rm. 5342, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los
Angeles, CA 90048-1865 (E-mail: chenp@cshs.org).
The costs of publication of this article were defrayed in part by the
payment of page charges. The article must therefore be hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
Am J Physiol Heart Circ Physiol 282: H1063–H1070, 2002;
10.1152/ajpheart.00633.2001.
0363-6135/02 $5.00 Copyright © 2002 the American Physiological Societyhttp://www.ajpheart.org H1063
RV epicardium was elicited by a solid state, frequency dou-
bled laser (Verdi, Coherent) at a wavelength of 532 nm. Laser
light was delivered to the RV with the use of multiple 1-mm
optical fibers (model SP-SF-960, FIS). The RVs were stained
for 20 min with 4-[-2(di-n-butylamino)-6-naphthyl]vi-
nyl]pyridinium (di-4-ANEPPS; Molecular Probes) 10 mol/l
in the perfusate. The emitting fluorescence was imaged with
a 12-bit digital charge-coupled device camera (model CA-D1–
0128T, Dalsa) through a 600-nm long-pass glass filter (model
R60, Nikon) and a 25-mm/f0.85 video lens (model CF25L,
Fujinon). Video images at 128  128 pixels were acquired
over 30  30 mm2 at 2.3 ms/frame and were transferred to a
personal computer with a frame grabber (Imaging Technol-
ogy). An excitation-contraction uncoupler was not used in the
current study. We recorded 2.3 s of data during each acqui-
sition.
A moving median filter was applied to the optical signal,
after which the signals were normalized so that the range of
the maximum signal amplitude was the same for each pixel.
The signals of each pixel were then spatially averaged. Each
pixel was then assigned a shade of gray between white (fully
depolarized) and black (fully repolarized). The computer first
finds every adjacent pair of pixels in the frame that cross the
average value of the data. If the intensity of the data on
which the line coincides is increasing, that edge is identified
as the wave front and colored red. Otherwise, if it is decreas-
ing, the edge is identified as the wave back and colored green.
A point where the red line meets the green line is a wave
break (14, 16, 24).
Transmembrane potential recordings and the APD restitu-
tion curves. Transmembrane potentials (TMPs) were re-
corded from an epicardial site using a standard glass micro-
electrode (9) or pure iridium metal microelectrode (18). For
APD measurements, a custom-written program selected as
time of activation (phase 0) if the voltage change over time
(dV/dt) at that time was greater than both of its temporal
neighbors and that the dV/dt was 5 V/s. The program then
looked forward in time to determine AP peak (voltage greater
than both neighbors) and looked backward in time to deter-
mine baseline (voltage less than both neighbors). The voltage
difference between the peak and the baseline was the AP
amplitude. The program then looked forward in time from
the AP peak until the voltage dropped by a value equal to
90% of the AP amplitude. That time is the time of 90%
repolarization and the temporal difference between phase 0
and 90% repolarization is the APD90. The diastolic interval
(DI) was defined as the difference between 90% repolariza-
tion and the onset of the next activation. Cycle length (CL)
was defined by the temporal difference between consecutive
activations. Manual editing was then performed to eliminate
noise.
Fig. 1. Transmembrane potentials (TMPs) at baseline (A), 10 min (B), and 20 min (C) after amiodarone infusion.
D: example of 90% action potential duration (APD90) and difference between 90% repolarization and onset of next
activation [diastolic interval (DI)] determination (from area marked by dashed lines in A). Note that the cycle
length (CL) and APD increased progressively with amiodarone infusion, evolving to a periodic activation resem-
bling ventricular tachycardia (VT).
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Figure 1 shows examples of TMP recordings during VF at
baseline and after amiodarone infusion (Fig. 1, A–C). Figure
1D shows an example of TMP analyses. The dashed lines
were drawn by manual extrapolation from the action poten-
tials that did not reach 90% repolarization. A “negative DI”
(12) can be estimated using the latter method.
We also recorded APD and DI during dynamic pacing (12).
This dynamic pacing protocol initially paced the RV at a
400-ms CL at twice the diastolic threshold current for eight
beats, followed immediately by eight beats of pacing at 350,
300, 280, 260, 240, 230, 220, 210, 200, 190, 180, 170, and
150 ms CLs.
The APD restitution curve was constructed by plotting
APD90 against the preceding DI. When DI was 0, we either
omitted those data (first method) or manually estimated the
negative DI, as shown in Fig. 1D (second method). The APD
restitution curve was estimated by single exponential fitting
with the use of ORIGIN software (Microcal).
Study protocol. In all isolated RVs, spontaneous VF oc-
curred during the isolation procedure and persisted in the
tissue bath. The patterns of activation were mapped while
TMPs were simultaneously recorded. Four RVs were defibril-
lated to allow APD recordings during dynamic pacing. VF
was then reinitiated by rapid pacing. Amiodarone (2.5 g/ml)
was then added to the perfusate for 30 min. TMP recordings
and optical mapping studies were repeated at 3-min inter-
vals. Reversibility of the effects of amiodarone was assessed
with drug-free Tyrode perfusion for 60 min. Inducibility of
VF was then tested by electrical stimulation, using the dy-
namic and fixed rate rapid pacing (CL as short as 50 ms)
protocols.
Data analysis. Reentrant wave fronts were identified, and
the sizes of their cores were measured by tracing the path of
the wave break points. If the path led to a closed loop, then
the area encircled by this loop was used as the core size (16).
The mean number of wavelets per frame was obtained from
the number of wavelets observed every 100 frames (230 ms
apart). Density of wavelets was obtained by dividing the
number of wavelets by the mapped area (3 cm  3 cm). The
incidence of spontaneous wave breaks was the ratio between
the total number of wave breaks observed divided by the total
duration of VF analyzed.
Statistical analysis. Data are presented as means  SD.
Student’s t-tests were used to compare means. Analysis of
variance with a Newman-Keuls test was used when multiple
comparisons were performed. A P value 0.05 was consid-
ered significant.
RESULTS
Table 1 summarizes the results of the study. At
pacing CL of 400 ms, amiodarone significantly de-
creased the maximum derivative of voltage relation to
time [(dV/dt)max], prolonged the APD90 and increased
the effective refractory period (Table 1).
Effects of amiodarone infusion on VF. VF CL, APD90,
and DI were prolonged by amiodarone infusion (Table
1). At the end of 30-min infusion, amiodarone resulted
in the conversion from VF to VT in 1 RV and VF
termination in 1 RV. In the remaining 4 RVs, VF
continued at a slower rate. At that time we replaced
the perfusate with amiodarone-free Tyrode solution to
evaluate the reversibility of the effect of the drug.
However, during the drug-free washout period, the VF
and VT CLs continued to lengthen and eventually all
RVs became quiescent. We then attempted to reinduce
VF up to 1 h after the beginning of washout. In no RV
was the VF inducible.
Amiodarone infusion progressively increased CL, re-
duced the density of wavelets, and the incidence of
spontaneous wave breaks (Table 1). Single-cell TMP
recordings showed that amiodarone resulted in a re-
duction of the low amplitude and fast activations in
VF, leading to the transition to VT or to a slower CL VF
(Fig. 1). We identified 11, 4, and 3 reentrant wave
fronts in VF episodes shown in Fig. 1, A–C. There was
a progressive increase of the CL of reentrant wave
front after amiodarone infusion (Table 1).
Video images revealed the effects of amiodarone on
wave dynamics during VF. At baseline, VF was char-
acterized by the presence of multiple irregular wave
fronts and spontaneous wave breaks (Fig. 2, top).
These gave rise to the irregular TMP recordings (Fig.
1A). Figure 2, bottom, illustrates typical activation
patterns during amiodarone infusion. A single wave
front propagated from the bottom right to the top left
corner of Fig. 2. The wavelet propagates repeatedly
without breaking, leading in this example to complete
elimination of spontaneous wave breaks in the mapped
region and a decrease in the number of wavelets. These
Table 1. Effects of amiodarone
Amiodarone, g/ml
Baseline 10 min 20 min
Pacing at 400 ms CL
(dV/dt)max, V/s 40.64.9 NA 27.42.6*
APD90, ms 19425 NA 20514*
Effective refractory
period, ms 20545 NA 23825*
Dynamic Pacing
Maximum APD90
restitution curve
slope by dynamic
pacing 2.160.44 1.230.02 1.200.14*
DI at maximum
APD90
restitution curve,
ms 22.02.6 30.513.4 34.09.8
VF
CL, ms 83.317.8 101.317.3 118.425.8*
APD90, ms 71.114.7 77.614.6 89.919.0*
DI, ms 12.29.0 23.712.7 28.617.0*
Wavelet density,
No./cm2 0.650.08 0.470.05* 0.410.10*
Spontaneous
wavebreaks,
No./s 35.03.4 20.92.7* 15.02.2*
Reentrant wave
front CL, ms 78.219.0 96.016.4 114.415.5*
Core size, mm2 0.90.3 2.51.0 4.13.8*
Maximum APD90
restitution slope
during VF 5.242.47 3.704.40 1.691.73*
DI at maximum
APD90
restitution curve
during VF, ms 0.460.5 0.81.1 0.80.3
Values are means  SD. CL, cycle length; NA, not available;
(dV/dt)max, maximum derivative of voltage in relation to time;
APD90, 90% action potential duration; DI, diastolic interval; VF,
ventricular fibrillation. *P  0.05 vs. baseline.
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changes also gave rise to the periodic activity in the
TMP recordings (Fig. 1C).
Reentrant wave fronts were occasionally seen during
VF at baseline (Fig. 3, left). The white arrows indicate
counterclockwise reentrant excitation and the tip of
the wave front propagates around the central core with
a period of 69 ms. The trajectory encircles an area of
0.7 mm2. During amiodarone infusion, reentrant wave
fronts were also observed. Figure 3, right, shows a
reentrant wave front with a period of 131 ms. A major
difference between the reentry circuit at baseline com-
pared with that during amiodarone infusion was the
size of the central core around which the wave front
rotated (6.8 mm2). Amiodarone infusion significantly
increased the central core area and increased the CL of
the reentrant wave fronts (Table 1).
Effects of amiodarone on APD restitution. Figure 4A
shows action potential recordings at baseline (left) and
during amiodarone infusion (Fig. 4A, right). During
dynamic pacing, the pacing intervals were fixed for
eight beats (S1), followed by an abrupt shortening of
pacing interval. The first beat of the shortened interval
is equivalent to a premature stimulus (S2). This figure
shows the AP induced by the last two S1 and the S2.
The shortest S1/S2 achieved at baseline was 160/150
ms, with a corresponding S2 APD of 113 ms. During
amiodarone infusion, the shortest S1/S2 increased to
200/190 ms, resulting in an S2 APD of 148 ms. Figure
4B shows an example of dynamic APD restitution
curve. Amiodarone increased the APD at all diastolic
intervals. Amiodarone significantly reduced the maxi-
mum slope of APD90 restitution curve. It also appeared
to have increased the shortest DI achieved during
dynamic pacing. However, the latter increase was not
statistically significant (Table 1). Figure 5 shows ex-
amples of APD restitution curves during VF at base-
line and during amiodarone infusion while RV was still
fibrillating. Amiodarone flattened the slope of APD90
restitution curve, particularly at short DIs. Table 1
shows the effects of amiodarone infusion in all RVs
studied. The DIs associated with the maximum slope of
APD90 restitution curve at baseline and during amio-
darone infusion were 10 ms (Table 1).
We also analyzed APD restitution curve by including
the negative DI in the graph. However, the APs with
negative DIs were 1% of the total number of APs
analyzed during baseline VF. Adding these negative
DIs did not change the restitution curve. For VF after
amiodarone infusion, there were fewer (Fig. 1B) or no
negative DIs recorded.
DISCUSSION
In this study we demonstrated that amiodarone in-
fusion reduced the slope of the APD restitution curve,
enlarged the core of reentrant wave front and sup-
pressed spontaneous wave breaks in VF. These
changes were associated with a decreased number of
Fig. 2. Activation patterns during ventricular fibrillation (VF) at baseline and during amiodarone infusion. At
baseline, 8 wave break points (yellow arrows) are present during the VF. At the time 0 ms, wave fronts marked a
and b are propagating upwards and wave front c is propagating to the left outside the mapped area. Wave front d
in its left portion propagates downward. The new wave front marked e breaks up in its central portion, splitting
into two wave fronts (E, top). After amiodarone infusion, a single wave front propagated from the lower right to the
top left corner (A–E, bottom). The wavelet propagates repeatedly without splitting at the site where wave-wave
interaction or spontaneous wave breaks occurred at baseline.
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wavelets, the termination of VF, or the transition from
VF to VT.
Mechanism of antiarrhythmic drug action. An expla-
nation for the antifibrillatory action of amiodarone is
its -blocking effects (8). Because the RVs were iso-
lated from the rest of the body, they were not influ-
enced by the systemic sympathetic activity. However,
local sympathetic nerve terminals might still be active
during VF. It is therefore possible that some of the
antifibrillatory effects of amiodarone in swine RV were
due to -blocking effects.
A second possible mechanism relates to effects of
amiodarone on the CL of the reentrant wave fronts.
Recently, Samie et al. (21) proposed that the size and
the dynamics of the core of the reentrant wave front, in
addition to the effective refractory period, are impor-
tant determinants of VF. In support of that hypothesis,
the authors demonstrated that verapamil increased
the size of the core and converted VF to VT in Langen-
dorff-perfused rabbit heart. In the present study, we
demonstrate that amiodarone increased the size of the
core and reduced the wave front number and sponta-
neous wave breaks. Therefore, our results are also
consistent with the hypothesis proposed by Samie et al.
(21).
A third possible mechanism relates to the wave-
length hypothesis of cardiac fibrillation (19). Wave-
length is a product of refractory period and conduction
velocity. Drugs that prolong wavelength are antifibril-
latory, whereas drugs that shorten wavelength may be
proarrhythmic. Amiodarone and other type III antiar-
rhythmic agents, such as d-sotalol, block the potassium
channels (11, 26) and prolong the APD and the refrac-
tory period (28). However, amiodarone also blocks the
sodium channel (3, 22) and decreases the conduction
velocity. A decreased conduction velocity might result
in a longer reentrant CL, which could independently
lengthen the APD. Furthermore, a uniform reduction
of conduction velocity could result in reduced conduc-
tion velocity dispersion, a factor that may be associated
with improved defibrillation efficacy (23). However,
because we mapped only the surface of a three-dimen-
sional RV, we cannot accurately determine the conduc-
tion velocity during VF. It cannot be determined in this
study whether or not amiodarone alters the wave-
length.
Fig. 3. Reentrant wave front during baseline VF (left) and during amiodarone infusion (right). A single rotation of
the reentrant wave front is displayed at baseline. White arrows indicate counterclockwise reentrant excitation and
the wave break point propagates around the central core area. Data are from the same preparation showing one
reentrant wave front rotated in a clockwise direction during amiodarone infusion. Note that a major difference
between the reentry circuit at baseline compared with that during amiodarone infusion was the central core area
around which the front rotated. Amiodarone infusion increased the core area from 0.7 to 6.8 mm2.
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A fourth possible explanation is the effect of amioda-
rone on APD restitution. The restitution hypothesis pos-
its that the APD restitution is a major factors underlying
wave break in VF (1, 4, 17, 27). Drugs that flatten the
APD restitution curve have antifibrillatory effects (5, 20).
A major finding of this study is that amiodarone results
in the flattening of the APD restitution slope. This effect
could explain the reduced incidence of wave breaks dur-
ing amiodarone administration. Therefore, our findings
are also compatible with the restitution hypothesis.
Fig. 4. A: APD recordings at baseline and during amiodarone infusion. In each panel, the last 2 paced action
potentials and a premature stimulus (S1 and S2, respectively), applied at progressively shorter coupling intervals,
are shown. B: APD restitution curves at baseline and during amiodarone infusion. Note that amiodarone increased
the APD at all DIs. A dashed line with a slope of 1 is included for comparison.
Fig. 5. Examples of APD restitution curve
during one episode of VF at baseline (A) and
one episode 10 min after (B) the commence-
ment of amiodarone infusion. Note that ami-
odarone reduced the slope of the APD resti-
tution curve, particularly at short DIs.
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Comparing amiodarone with bretylium and vera-
pamil. Bretylium and verapamil are also effective in
flattening the restitution curve (5, 20) but are less
useful than amiodarone in treating or preventing clin-
ical VF in human patients. Bretylium (10) results in
norepinephrine release during initial administration.
It also results in significant orthostatic hypotension
and is therefore poorly tolerated. For verapamil to
flatten the restitution curve, a concentration of 1,000–
3,000 ng/ml is needed (2, 20). This concentration is at
least twice as high as what can be achieved with a
maximum oral dose of verapamil (120 mg every 6 h)
(25). These data indicate that a very high (or toxic) dose
of verapamil is needed to reach a serum concentration
sufficient to flatten the restitution curve. In compari-
son, we showed in this study that amiodarone 2.5
g/ml may flatten restitution curve and exerts signifi-
cant effects on the patterns of activation in VF. This
serum concentration can be easily achieved with 5
mg/kg intravenous amiodarone (6). Therefore, amioda-
rone is clinically more useful than verapamil or bretyl-
ium in treating patients with VT and VF.
Limitation of the study. The first limitation is that
acute effects of amiodarone cannot be reversed. There-
fore, we were not able to test whether or not the effects
of amiodarone are reversible on washout. A second
limitation is that we used isolated normal RV in the
study. It is unclear whether or not the results are
applicable to diseased human hearts. A third limita-
tion is that calcium channel blockers (20) and bretyl-
ium (5) are also known to flatten APD restitution.
However, these drugs are not as effective as amioda-
rone in treating human VF. Therefore, flattening of
APD restitution may only partially explain the antifi-
brillatory effects of amiodarone.
In conclusion, amiodarone infusion reduced sponta-
neous wave breaks and the density of VF wavelets. It
might terminate VF or convert VF to VT. These effects
were associated with the flattening of APD restitution
slope and increased the core size of reentrant wave
fronts.
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